No abstract

No abstract

Urinary bladder augmentation with a segment of the stomach, i.e., gastrocystoplasty, has been used to improve capacity and compliance in patients with bladder dysfunction. In the present study, rats were subjected to gastrocystoplasty (using the oxyntic segment) with or without fundectomy (removal of the oxyntic part of stomach), and the acid secretion in the augmented bladder was measured. In freely fed rats, the pH values were neutral and not significantly decreased in the rats subjected to gastrocystoplasty with or without fundectomy compared to controls (no operation or sham operation). In response to food intake after being fasted, the rats subjected to gastocystoplasty + fundectomy produced significant amounts of acid. Immunohistochemical examination revealed that the ECL cells and parietal cells seemed to be normal in rats with gastrocystoplasty alone, and that micronodules of ECL appeared to develop in rats with gastrocystoplasty + fundectomy. We suggest that the rats subjected to gastrocystoplasty + fundectomy are capable of producing acid secretion in the bladder, probably due to the secretagogue and trophic effects of gastrin on the ECL cells in the segment of the oxyntic mucosal segment of the bladder.

Gastric ECL-cell hyperplasia and carcinoids (ECLoma) develop after 1 year in rats treated with omeprazole or 2 months in Mastomys treated with loxtidine. The aim of this study was to examine the ultrastructure of ECL cells in Mastomys after loxtidine treatment with an attempt to evaluate whether an impairment of autophagy was involved in the tumorigenesis. Mastomys were given loxtidine for 8 or 27 weeks. Morphological analysis of ECL cells showed that (1) cell size was not increased after 8 or 27 weeks; (2) secretory vesicles, a hallmark feature of welldifferentiated ECL cells, were unchanged after 8 weeks but reduced after 27 weeks; (3) granules were reduced after 8 or 27 weeks; (4) microvesicles were unchanged after the treatment; and (5) vacuoles and lipofuscin bodies were found occasionally after 8 weeks but not at 27 weeks. In addition, the appearance of ECL-cell ultrastructure differed between loxtidine-treated Mastomys and rats treated with omeprazole or subjected to antrectomy, but was similar between Mastomys treated with loxtidine for 27 weeks and mice deficient in CCK(2) receptor. We suggest that the ultrastructure of ECL cells in Mastomys after long-term treatment with loxtidine displayed an impaired formation of vacuoles and lipofuscin bodies, markers of the autophagic pathway.